×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Tags: omarigliptin | diabetes | treatment | merck

Once-Weekly Diabetes Drug Found Effective

Once-Weekly Diabetes Drug Found Effective
(Copyright AP)

Wednesday, 16 September 2015 11:11 AM EDT

Merck & Co said its experimental once-weekly diabetes drug was found to be as good as its blockbuster Januvia, which is taken once a day.

The late-stage study compared 25 mg of the drug, omarigliptin, to 100 mg of Januvia. Both treatments belong to a family of drugs called DPP-4 inhibitors that help lower blood sugar levels.

Fifty-one percent of patients taking omarigliptin reached required sugar levels at week 24, compared with 49 percent of those who took Januvia.

Merck, which has already applied for marketing approval for the drug in Japan, said it would submit its application in the United States by the end of 2015.

Januvia, among Merck's best-selling drugs, raked in sales of about $4 billion in 2014, plus another $1.8 billion for the related combination product Janumet.

© 2024 Thomson/Reuters. All rights reserved.


Health-News
Merck Co said its experimental once-weekly diabetes drug was found to be as good as its blockbuster Januvia, which is taken once a day. The late-stage study compared 25 mg of the drug, omarigliptin, to 100 mg of Januvia. Both treatments belong to a family of drugs called...
omarigliptin, diabetes, treatment, merck
131
2015-11-16
Wednesday, 16 September 2015 11:11 AM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
Find Your Condition
Get Newsmax Text Alerts
TOP

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved